<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01922583</url>
  </required_header>
  <id_info>
    <org_study_id>CAUY922ATW02T(201302063MIPD)</org_study_id>
    <secondary_id>1020009413</secondary_id>
    <nct_id>NCT01922583</nct_id>
  </id_info>
  <brief_title>AUY922 in Patient With Stage IV NSCLC</brief_title>
  <acronym>NSCLC</acronym>
  <official_title>A Multi-center Phase II Study of AUY922 in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) With Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed After One Line of Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, multicenter phase II trial in patients with stage IV EGFR&#xD;
      T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged&#xD;
      NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:&#xD;
&#xD;
      This is an open-label, single-arm, multicenter phase II trial in patients with stage IV EGFR&#xD;
      T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged&#xD;
      NSCLC (n = 9 x 7)&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary objective(s):&#xD;
&#xD;
      To define the objective response rate by RECIST 1.1 of AUY922 in patients with stage IV EGFR&#xD;
      T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged&#xD;
      NSCLC&#xD;
&#xD;
      Secondary objective(s):&#xD;
&#xD;
      (1) To define the disease control rate (complete response + partial response + stable disease&#xD;
      &gt;=24 weeks) of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon,&#xD;
      HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC. (2) To determine the&#xD;
      progression-free survival of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and&#xD;
      other uncommon, HER2, KRAS, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC. (3) To&#xD;
      determine the overall survival of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20&#xD;
      and other uncommon, HER2, KRAS, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC.&#xD;
&#xD;
      Exploratory Objective(s):&#xD;
&#xD;
      To study the pharmacodynamics of circulating tumor cells and plasma proteins.&#xD;
&#xD;
      Planned number of subjects: A total of 63 patients for the first stage of this study in 1 - 3&#xD;
      centers in Taiwan.&#xD;
&#xD;
      Patient population:&#xD;
&#xD;
        1. Stage IV (by AJCC 7th edition) NSCLC.&#xD;
&#xD;
        2. EGFR T790M mutation; EGFR exon 20 and other uncommon mutation; HER2 mutation; BRAF&#xD;
           mutation; ALK translocation; ROS1 translocation; or RET translocation in tumor samples.&#xD;
&#xD;
        3. One line of prior systemic therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Patients will be followed up for 2 years(post disease progression)</time_frame>
    <description>To define the by RECIST 1.1 of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy, progression-free survival (PFS)</measure>
    <time_frame>Patients will be followed up for PFS and OS for 2 years.(post disease progression)</time_frame>
    <description>Patients will be followed for progression-free survival (PFS) and overall survival (OS) which will be analyzed by using a Kaplan-Meier curve.&#xD;
Patients will be followed up for PFS and OS for 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>Patients will be followed up for OS for 2 years.(post disease progression)</time_frame>
    <description>Patients will be followed for overall survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Vial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AUY922</intervention_name>
    <description>AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression</description>
    <arm_group_label>Vial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven diagnosis of stage IV NSCLC (AJCC 7th) which&#xD;
             had been treated with one systemic therapy.&#xD;
&#xD;
          -  One of the molecular alterations as follows:&#xD;
&#xD;
               -  EGFR mutations in exon 20 T790M.&#xD;
&#xD;
               -  EGFR mutations in exon 20; in-frame duplication and/or insertion (e.g.&#xD;
                  A767_V769dupASV or H773_V774insH) or point mutations other than T790M; or other&#xD;
                  uncommon mutations.&#xD;
&#xD;
               -  HER2 mutation in exon 20; in-frame duplication and/or insertion (e.g. YVMA&#xD;
                  776-779 ins).&#xD;
&#xD;
               -  BRAF mutation in exon 15; point mutation (e.g. V600E) or in exon 11; point&#xD;
                  mutation (e.g. G469A, D594G).&#xD;
&#xD;
               -  ALK translocation resulting in EML4-ALK, KIF5B-ALK, or TFG-ALK fusion as&#xD;
                  determined by an ALK break apart FISH assay and defined by an increase in the&#xD;
                  distance of 5' and 3' ALK probes (split 5'-3') or the loss of the 5' probe&#xD;
                  (single 3'). Positive ALK results from other methods such as immunohistochemistry&#xD;
                  (IHC) or reverse transcriptase polymerase chain reaction testing may also be&#xD;
                  acceptable.&#xD;
&#xD;
               -  ROS1 translocation resulting in CD74-ROS1 or SLC34A2-ROS1, etc.&#xD;
&#xD;
               -  RET translocation resulting in KIF5B-RET fusion, etc.&#xD;
&#xD;
          -  Patients with brain metastases are eligible if treated and neurologically stable for&#xD;
             at least 2 weeks and is not taking any steroid.&#xD;
&#xD;
          -  Any prior chemotherapy, targeted therapy (monoclonal antibodies), or major surgeries&#xD;
             must have had completed at least 4 weeks before initiation of study medication. Any&#xD;
             prior targeted therapy (tyrosine kinase inhibitors), radiotherapy or minor surgeries&#xD;
             must have had completed at least 2 weeks before initiation of study medication. Any&#xD;
             acute toxicity must have recovered to &lt;=grade 1 (except for alopecia).&#xD;
&#xD;
          -  Patients must have measurable or evaluable disease as per RECIST version 1.1.&#xD;
&#xD;
          -  20 years of age or older&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Adequate organ function as defined by the following criteria:&#xD;
&#xD;
               -  Bone marrow function&#xD;
&#xD;
               -  Hemoglobin &gt;=8.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt;=1500/uL&#xD;
&#xD;
               -  Platelets &gt;=100,000/uL&#xD;
&#xD;
               -  Hepatic function&#xD;
&#xD;
               -  Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) &lt;=3.0 x&#xD;
                  upper limit of normal (ULN) or AST and ALT &lt;=5.0 x ULN if there is liver&#xD;
                  metastasis&#xD;
&#xD;
               -  Total serum bilirubin &lt;=1.5 x ULN Renal function&#xD;
&#xD;
               -  Creatinine &lt;= 1.5 x ULN or creatinine clearance &gt;=45 mL/min&#xD;
&#xD;
          -  Able to communicate well with the investigator, to understand and comply with the&#xD;
             requirements of the study. Understand and sign the written informed consent.&#xD;
&#xD;
          -  Patients must use effective methods of contraception during the study period and for&#xD;
             at least 90 days following study completion (excluding surgically sterile male&#xD;
             patients, surgically sterile or postmenopausal female patients).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently on other therapeutic clinical trials&#xD;
&#xD;
          -  Prior treatment of HSP90 inhibitors&#xD;
&#xD;
          -  Any of the following within 3 months before initiation of study medication&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Coronary artery bypass graft&#xD;
&#xD;
               -  Congestive heart failure NYHA functional class III or IV&#xD;
&#xD;
               -  Cerebral vascular accident&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Uncontrolled hypertension at screening&#xD;
&#xD;
          -  Ongoing cardiac arrhythmias of NCI CTCAE grade &gt;=2&#xD;
&#xD;
          -  Active infection requiring antibiotics&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Prior malignancy within the past 5 years (excluding non-melanoma skin cancer, cervical&#xD;
             carcinoma in situ, superficial bladder cancer, and early prostate cancer).&#xD;
&#xD;
          -  Active hepatitis B or C; positive HIV test result.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Hsin Yang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC, EGFR mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

